Xerostomia affects a significant portion of the population and is commonly linked to polypharmacy, radiation therapy, autoimmune conditions, orthodontic treatment, and ageing. Left untreated, it can lead to an increased risk of dental caries, oral infections, and difficulties in speech and swallowing, significantly compromising oral health and quality of life.

What sets Xerostom apart is its clinically proven efficacy. Research has shown that Xerostom increases salivary flow by up to 200% (Ship et al., 2007), offering long-lasting hydration and symptom relief. Its unique formulation, enriched with olive oil, betaine, and xylitol, has been extensively studied for its effectiveness in post-radiotherapy and medication-induced dry mouth (Martín et al., 2017).

Key clinical benefits of Xerostom:

• Clinically proven to increase saliva production (Ship et al., 2007).
• Alcohol-free and non-irritating formulation, suitable for long-term use (Davies et al., 2001).
• Enriched with Xylitol, Vitamin E, and Betaine, helping to maintain oral mucosal hydration and prevent bacterial overgrowth.
• Comprehensive range to address different levels of dry mouth and lifestyle choices.

Dental professionals are invited to Stand D70 to explore the clinical applications of Xerostom and learn how it can enhance patient care.

For further details or to place an order, contact Oraldent at 01480 862080, email info@oraldent.co.uk, or visit www.oraldent.co.uk.

References:

·       Ship J.A., et al. (2007). Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. Journal of Oral Rehabilitation, 34(7), 724-732.

·       Davies A.N., Broadley K., Beighton D. (2001). Xerostomia in patients with advanced cancer. Journal of Pain and Symptom Management, 22(4), 820–825.

·       Martín, M., et al. (2017). Products based on olive oil, betaine, and xylitol in post-radiotherapy xerostomia. Reports of Practical Oncology and Radiotherapy, 22(1), 71-76.